In recent years, there’s been a scarcity of high quality, revenue-generating biopharma assets. This dearth, coupled with larger pharma’s growth requirements, has led to a significant run up in valuations of private and public biotech assets. As a result, organizations have been forced to adopt new and more advanced valuation techniques to appropriately evaluate acquisition targets.

Representatives from the industry’s most successful pharma/biotech organizations will share insights and best practices for capturing and analyzing the most relevant aspects in designing a comprehensive valuation for M&A and what challenges remain.

Ability Level: Intermediate

Session ID: 503077